SG10201913709QA - Nitrobenzyl derivatives of anti-cancer agents - Google Patents

Nitrobenzyl derivatives of anti-cancer agents

Info

Publication number: SG10201913709QA
Authority: SG; Singapore
Prior art keywords: cancer agents; nitrobenzyl derivatives; nitrobenzyl; derivatives; cancer
Prior art date: 2015-04-02

Ascentawits Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-01Application filed by Ascentawits Pharmaceuticals LtdfiledCriticalAscentawits Pharmaceuticals Ltd

2020-03-30Publication of SG10201913709QApublicationCriticalpatent/SG10201913709QA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Crystallography & Structural Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Epoxy Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SG10201913709QA2015-04-022016-04-01Nitrobenzyl derivatives of anti-cancer agentsSG10201913709QA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562142352P	2015-04-02	2015-04-02

Publications (1)

Publication Number	Publication Date
SG10201913709QAtrue SG10201913709QA (en)	2020-03-30

Family

ID=57006330

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201707375UASG11201707375UA (en)	2015-04-02	2016-04-01	Nitrobenzyl derivatives of anti-cancer agents
SG10201913709QASG10201913709QA (en)	2015-04-02	2016-04-01	Nitrobenzyl derivatives of anti-cancer agents

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201707375UASG11201707375UA (en)	2015-04-02	2016-04-01	Nitrobenzyl derivatives of anti-cancer agents

Country Status (13)

Country	Link
US (2)	US10829437B2 (en)
EP (1)	EP3277381A4 (en)
JP (2)	JP6612892B2 (en)
KR (2)	KR102001910B1 (en)
CN (2)	CN112142692A (en)
AU (1)	AU2016244000B2 (en)
BR (1)	BR112017021167A2 (en)
CA (1)	CA2981494C (en)
IL (1)	IL254769B (en)
MY (1)	MY198613A (en)
SG (2)	SG11201707375UA (en)
TW (1)	TWI730957B (en)
WO (1)	WO2016161342A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10037382B2 (en)	2012-10-29	2018-07-31	Kyocera Corporation	Surface acoustic wave sensor
US10131683B2 (en)	2014-07-17	2018-11-20	Molecular Templates, Inc.	TH-302 solid forms and methods related thereto
BR112017019287B1 (en)	2015-03-10	2024-01-02	Obi Pharma, Inc	Compound, and pharmaceutically acceptable composition
CN112142692A (en)*	2015-04-02	2020-12-29	深圳艾欣达伟医药科技有限公司	Nitrobenzyl derivative anticancer agents
WO2016210175A1 (en)	2015-06-24	2016-12-29	Threshold Pharmaceuticals, Inc.	Aziridine containing dna alkylating agents
TW201919644A (en)*	2017-09-29	2019-06-01	台灣浩鼎生技股份有限公司	Method for treating leukemia
IL275766B2 (en)	2018-01-17	2024-05-01	Aurigene Oncology Ltd	Substituted alkynylene compounds as anticancer agents
CN110693892A (en)*	2018-07-09	2020-01-17	深圳艾欣达伟医药科技有限公司	Use of compound for preparing medicine for preventing, treating or improving pain
JP2022533346A (en)*	2019-05-13	2022-07-22	アセンタウィッツファーマシューティカルズリミテッド	Fluorine-containing compounds and their anti-cancer medical uses
KR20220030256A (en)*	2019-07-01	2022-03-10	아센타위츠 파마슈티컬즈 리미티드	AKR1C3 inhibitors and medical uses thereof
WO2021000862A1 (en)*	2019-07-01	2021-01-07	深圳艾欣达伟医药科技有限公司	Akr1c3 inhibitor and medical use
CN110357897A (en)*	2019-07-26	2019-10-22	上海健康医学院	A kind of camptothecin derivative with anti-tumor activity and its preparation method and application
CN110713515B (en)*	2019-09-29	2023-03-24	南京益唯森生物科技有限公司	Metronidazole-sarcosyl-histidine dipeptide compound and preparation and application thereof
CN114555574B (en)*	2019-10-12	2024-04-12	深圳扬厉医药技术有限公司	Chromans targeting aldehyde ketone reductase 1C3
CN114555614A (en)*	2019-11-01	2022-05-27	深圳艾欣达伟医药科技有限公司	Anti-cancer compounds as non-PGP substrates
CN112904026A (en)*	2019-12-03	2021-06-04	深圳艾欣达伟医药科技有限公司	Correlating AKR1C3 enzyme expression level through prostaglandin content and screening administration application
BR112023003973A2 (en)	2020-09-02	2023-04-11	Ascentawits Pharmaceuticals Ltd	AKR1C3 DETECTION METHOD AND DIAGNOSTIC KIT FOR AKR1C3 DETECTION AND USE OF THE SAME
EP4215523A4 (en)*	2020-09-18	2024-03-06	Shenzhen Vybio Pharmaceutical Technology Co., Ltd.	Isochroman compound
AU2021431102A1 (en)	2021-03-05	2023-09-21	Ascentawits Pharmaceuticals, Ltd.	Primer-probe composition, kit, and detection method
CN117321064A (en)*	2021-06-11	2023-12-29	深圳艾欣达伟医药科技有限公司	Gemcitabine anticancer derivative and anticancer medical application thereof
CN115869325A (en)	2021-09-26	2023-03-31	深圳艾欣达伟医药科技有限公司	Use of compound for preparing medicine for treating KRAS mutant cancer patient
KR20240110013A (en)*	2021-11-05	2024-07-12	아센타위츠 파마슈티컬즈 리미티드	AKR1C3-activated DNA alkylating agent and its medical applications
EP4494643A4 (en)	2022-03-15	2025-09-10	Ascentawits Pharmaceuticals Ltd	METHOD FOR TREATING A PATIENT WITH BRCA-MUTATED CANCER
WO2023226959A1 (en)	2022-05-23	2023-11-30	深圳艾欣达伟医药科技有限公司	Method for treating cancer by combining alkylating agent prodrug and cell cycle inhibitor
WO2023237080A1 (en)	2022-06-10	2023-12-14	深圳艾欣达伟医药科技有限公司	Method for treating cancer patient with akr1c3 enzyme-activated prodrug
WO2024125595A1 (en)*	2022-12-14	2024-06-20	深圳艾欣达伟医药科技有限公司	Gemcitabine anti-cancer derivative, anti-cancer pharmaceutical use and preparation method therefor
WO2024251193A1 (en)*	2023-06-06	2024-12-12	深圳艾欣达伟医药科技有限公司	Correlation of akr1c3 enzyme expression level with kras mutation, and medical use
WO2025026214A1 (en)*	2023-07-28	2025-02-06	深圳艾欣达伟医药科技有限公司	Treatment of p53 gene mutation or defect negative cancer and tumor patients

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5306727A (en)	1993-04-30	1994-04-26	Research Corporation Technologies, Inc.	Phosphoramidates useful as antitumor agents
TW200528436A (en)*	1999-09-22	2005-09-01	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
US6482953B1 (en)	2001-12-03	2002-11-19	Eastman Kodak Company	2-benzyloxy-4-nitro-5-substituted-acylanilide compounds and method of using them
ZA200507752B (en)	2003-03-28	2007-01-31	Threshold Pharmaceuticals Inc	Compositions and methods for treating cancer
US20040214798A1 (en)	2003-04-22	2004-10-28	Longqin Hu	Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation
DE102004020570A1 (en)	2004-04-27	2005-11-24	Bayer Healthcare Ag	Substituted phenylaminopyrimidines
MX2007006102A (en)*	2004-11-22	2007-07-11	Threshold Pharmaceuticals Inc	Tubulin binding anti cancer agents and prodrugs thereof.
NZ565378A (en)	2005-06-29	2011-03-31	Threshold Pharmaceuticals Inc	Phosphoramidate alkylator prodrugs
CA2633760A1 (en)	2005-12-21	2007-07-05	Abbott Laboratories	Anti-viral compounds
WO2007098089A2 (en)	2006-02-17	2007-08-30	Novacea, Inc.	Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs
ES2884044T3 (en)	2006-12-26	2021-12-10	Immunogenesis Inc	Phosphoramidate alkylating prodrug for cancer treatment
WO2008151253A1 (en)	2007-06-04	2008-12-11	Threshold Pharmaceuticals, Inc.	Hypoxia activated prodrugs of antineoplastic agents
WO2009018163A1 (en)*	2007-07-27	2009-02-05	Threshold Pharmaceuticals, Inc.	Hypoxia activated prodrugs of anthracyclines
WO2010044686A1 (en)*	2008-10-17	2010-04-22	Auckland Uniservices Limited	Akr1c3 as a biomarker, methods of selecting and treating patients based upon an akr1c3 profile and compounds for use therein
JP5765634B2 (en)	2008-10-21	2015-08-19	スレッシュホールドファーマシューティカルズ，インコーポレイテッド	Treatment of cancer with hypoxia activated prodrugs
BR112012012471A2 (en)*	2009-11-24	2016-11-01	Univ Rutgers	compounds, compositions and methods for treating protozoal infections
JP6066421B2 (en)	2010-07-12	2017-01-25	スレッショルドファーマシューティカルズ、インク．ＴｈｒｅｓｈｏｌｄＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Method of administering hypoxia activated prodrug and angiogenesis inhibitor for the treatment of cancer
CN102924507A (en)*	2011-11-10	2013-02-13	安徽四维药业有限公司	An anti-tumor compound and its preparation method, application, and pharmaceutical compositions
JP6356160B2 (en)*	2013-02-25	2018-07-11	ザスクリプスリサーチインスティテュート	Neoceptin: small molecule adjuvant
CN105814032A (en)	2013-10-10	2016-07-27	默克专利有限公司	Synthesis of 1-alkyl-2-amino-imidazole-5-carboxylates via Cα-substituted N-alkyl-glycine ester derivatives
BR112017019287B1 (en)*	2015-03-10	2024-01-02	Obi Pharma, Inc	Compound, and pharmaceutically acceptable composition
CN112142692A (en)	2015-04-02	2020-12-29	深圳艾欣达伟医药科技有限公司	Nitrobenzyl derivative anticancer agents
WO2016210175A1 (en)	2015-06-24	2016-12-29	Threshold Pharmaceuticals, Inc.	Aziridine containing dna alkylating agents
CN108290911B (en)	2015-11-16	2020-05-08	深圳艾欣达伟医药科技有限公司	(R) -and (S) -1- (3- (3-N, N-dimethylaminocarbonyl) phenoxy-4-nitrophenyl) -1-ethyl-N, N' -bis (ethylene) phosphoramidate, compositions, and methods of use and preparation thereof

2016
- 2016-04-01CNCN202011030727.6Apatent/CN112142692A/enactivePending
- 2016-04-01SGSG11201707375UApatent/SG11201707375UA/enunknown
- 2016-04-01EPEP16774352.5Apatent/EP3277381A4/enactivePending
- 2016-04-01CACA2981494Apatent/CA2981494C/enactiveActive
- 2016-04-01TWTW105110688Apatent/TWI730957B/enactive
- 2016-04-01MYMYPI2017703650Apatent/MY198613A/enunknown
- 2016-04-01SGSG10201913709QApatent/SG10201913709QA/enunknown
- 2016-04-01BRBR112017021167-0Apatent/BR112017021167A2/ennot_activeApplication Discontinuation
- 2016-04-01KRKR1020177026148Apatent/KR102001910B1/enactiveActive
- 2016-04-01CNCN201680020013.2Apatent/CN108136214B/enactiveActive
- 2016-04-01WOPCT/US2016/025665patent/WO2016161342A2/ennot_activeCeased
- 2016-04-01USUS15/563,481patent/US10829437B2/enactiveActive
- 2016-04-01JPJP2017551661Apatent/JP6612892B2/enactiveActive
- 2016-04-01AUAU2016244000Apatent/AU2016244000B2/enactiveActive
- 2016-04-01KRKR1020197017313Apatent/KR102276681B1/enactiveActive
2017
- 2017-09-28ILIL254769Apatent/IL254769B/enactiveIP Right Grant
2019
- 2019-07-24JPJP2019135817Apatent/JP6947781B2/enactiveActive
2020
- 2020-09-29USUS17/036,588patent/US11535585B2/enactiveActive

Also Published As

Publication number	Publication date
WO2016161342A2 (en)	2016-10-06
JP6612892B2 (en)	2019-11-27
JP6947781B2 (en)	2021-10-13
JP2019178172A (en)	2019-10-17
MY198613A (en)	2023-09-11
WO2016161342A3 (en)	2016-11-10
IL254769A0 (en)	2017-12-31
CN108136214B (en)	2020-08-28
EP3277381A4 (en)	2018-12-05
SG11201707375UA (en)	2017-10-30
US20180086693A1 (en)	2018-03-29
HK1250959A1 (en)	2019-01-18
CN112142692A (en)	2020-12-29
KR20170127463A (en)	2017-11-21
CA2981494A1 (en)	2016-10-06
KR102276681B1 (en)	2021-07-13
KR102001910B1 (en)	2019-07-19
US11535585B2 (en)	2022-12-27
US10829437B2 (en)	2020-11-10
KR20190075145A (en)	2019-06-28
CA2981494C (en)	2023-09-05
TWI730957B (en)	2021-06-21
CN108136214A (en)	2018-06-08
IL254769B (en)	2020-05-31
TW201706267A (en)	2017-02-16
BR112017021167A2 (en)	2018-07-03
AU2016244000B2 (en)	2020-07-02
EP3277381A2 (en)	2018-02-07
JP2018511612A (en)	2018-04-26
US20210017120A1 (en)	2021-01-21
AU2016244000A1 (en)	2017-10-12

Publication	Publication Date	Title
IL254769B (en)	2020-05-31	Nitrobenzyl derivatives of anti-cancer agents
ZA201705092B (en)	2019-06-26	Substituted nucleoside derivatives useful as anticancer agents
ZA201800826B (en)	2021-08-25	Substituted oxopyridine derivatives
SG11201706729SA (en)	2017-09-28	Derivatives of sobetirome
IL256548A (en)	2018-02-28	Phenoxymethyl derivatives
IL253381A0 (en)	2017-09-28	9h-pyrrolo-dipyridine derivatives
IL263050B (en)	2021-09-30	Derivatives of sobetirome
IL285882A (en)	2021-09-30	Therapeutic uses of l-4-chlorokynurenine
IL249581A0 (en)	2017-02-28	Isoindolinone derivatives useful as antiviral agents
IL258438B (en)	2020-06-30	2-aminoquinazoline derivatives as p70s6 kinase inhibitors
IL251005B (en)	2020-03-31	Pyrido-oxazinone derivatives
SG11201704527VA (en)	2017-07-28	Anti-cancer compounds
EP3481806C0 (en)	2023-06-07	4-anilino-quinoline compounds as anti-cancer agents
PT3395819T (en)	2023-07-05	Crystal form of substituted aminopyran derivative
GB201513979D0 (en)	2015-09-23	Synthesis of benzodiazepine derivatives
ZA202000996B (en)	2022-07-27	Anti-cancer agent
GB201512635D0 (en)	2015-08-26	Uses of therapeutic compounds

Movatterモバイル変換

SG10201913709QA - Nitrobenzyl derivatives of anti-cancer agents - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (1)

Family

ID=57006330

Family Applications (2)

Family Applications Before (1)

Country Status (13)

Families Citing this family (28)

Family Cites Families (24)

Also Published As

Similar Documents